|
Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep worldwide. It has been approved by the U.S. Food and Drug Administration (FDA) for once daily treatment and prophylaxis of deep vein thrombosis and pulmonary embolism.〔Hull et al. NEJM 1992;326,15:975-982''〕 Tinzaparin sodium is the only low molecular weight heparin shown to be safe in pregnancy and in critically ill people with renal failure at both treatment and prophylaxis dose levels. It can be given subcutaneously by syringe, or intravenously.〔Farmaceutiska Specialiteter i Sverige - the Swedish official drug catalog. (Fass.se ) > Innohep〕 It was manufactured by Leo pharmaceutical company, who withdrew the product from the US in 2011 due to low sales and a contamination issue.〔http://www.ashp.org/DrugShortages/NotAvailable/Bulletin.aspx?id=749〕 ==F.D.A approved indications== In the United States, tinzaparin is FDA approved for the following indications: *1-Prophylaxis of DVT in medically ill and elderly patient. *2-Total hip & knee replacement, *3-Extended hip-replacement, *4-Abdominal surgery. *5-Treatment of DVT with or without PE. *6-prophylaxis and treatment of DVT in pregnant women. *7-as an assistant in the process of In Vitro Fertilization (IVF). 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Tinzaparin sodium」の詳細全文を読む スポンサード リンク
|